US-based SCIEX, a global leader in life science analytical technologies, has announced the launch of new native fluorescence detection on the BioPhase 8800 system. To ensure drug safety and efficacy, multiple critical quality attributes such as purity, fragmentation, aggregation, and post-translational modifications need to be well-characterised and monitored.
Assays like CE-SDS and cIEF offer automated and quantitative quality assessments of protein therapeutics and are routinely used throughout the drug development process and as a product release test. Adding native fluorescence detection elevates these gold standard assays to improve confidence in data and accelerate the drug development pipeline.
“We frequently hear from our customers, that managing large sample sets with limited material and tight timelines is a challenge. Native fluorescence detection on the BioPhase 8800 system addresses this challenge by providing fast, accurate analysis, which is critical for advancing the best candidates in development. We’ve already seen it produce notable time savings, improved precision, and better confidence when identifying new impurity peaks and low-abundant species,” said Jose Castro-Perez, Vice President, Product Management at SCIEX.
